Notable responses included a sustained complete response in an ovarian cancer patient with a BRCA2 R3052W mutation, partial responses in a soft tissue sarcoma patient (BRCA1 V788fs*10 mutation) and a salivary gland cancer patient (BRCA1 M1I mutation), and prolonged partial response in a breast cancer patient (BRCA1 Q380* mutation). Here, BRCA1 is linked to breast carcinoma.